Adagene Inc. (ADAG) is a highly innovative biopharmaceutical company focused on the research, development, and commercialization of antibody-based therapeutics for the treatment of cancer. Established in 2011 and headquartered in Suzhou, China, with offices in San Francisco and San Diego, the firm operates with a dynamic and ambitious vision to fulfill unmet medical needs on a global scale.
Unique to Adagene is their pioneering Dynamic Precision Library and Safe Harbor platform. This innovative technology empowers them to create antibody drugs with higher diversity and better specificity. It allows for comprehensive exploration of all possible antibody sequences in a given antibody gene which makes it possible to develop best-in-class and first-in-class antibody drugs.
Key product candidates of Adagene include ADG106 and ADG126, both undergoing rigorous phase 1 trials, and demonstrating promising abilities in inhibiting tumor growth. Adagene’s research pipeline also includes ADG116, currently in pre-clinical stage that targets CTLA-4, a solid-tumor immune checkpoint pathway.
In a globally competitive field, Adagene stands out for its commitment to rigorous science and novel technology. Top investors including top-tier global healthcare investors F-Prime Capital, Eight Roads Ventures, WuXi Corporate Venture Fund, Sequoia China, and General Atlantic believe in its potential and have backed the company, generating significant capital for research, development, and market expansion.
The company's prestigious lineup of seasoned professionals, led by Dr. Peter Luo, combines expertise in the biopharmaceutical industry with a deep understanding of the underlying science that drives innovation in this sector. Since its inception, the company has grown to over 100 employees, each contributing to Adagene’s mission to revolutionize the way cancer is treated on a global scale.
Adagene Inc. (ADAG) made its initial public offering (IPO) on the NASDAQ stock exchange in February 2021, with a retail price of $19 per share, further enhancing its position in the global pharmaceutical industry. Despite the challenges brought by the global pandemic, the company has remained resilient, continuing its pursuit of novel oncology therapeutics.
In summary, Adagene Inc. (ADAG) is not only addressing unmet needs in oncology but is also at the forefront of technological advancement in the biopharmaceutical sector. With a progressive vision and a robust pipeline of novel therapies, the firm is making significant strides in its mission to advance patient care in the field of cancer treatment.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Adagene Inc. has announced the dosing of the first patient in a Phase 1 study combining its masked anti-CTLA-4 SAFEbody, muzastotug, with Incyte’s TGFβR2 × PD-1 bispecific antibody, INCA33890. This study targets third-line microsatellite stable colorectal cancer patients, including those with liver metastases, to evaluate if the combination can enhance antitumor responses. The collaboration aims to leverage the complementary mechanisms of both therapies to broaden clinical benefit and maintain an acceptable safety profile.
Adagene Inc. announced its senior management will participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference from November 9-11, 2026, in Boston, MA. The company will host a fireside chat and one-on-one meetings, with a webcast of the chat available on its investor relations website. Adagene, a clinical-stage biotechnology company, is focused on developing novel antibody-based cancer immunotherapies using computational biology and AI.
Adagene Inc. (Nasdaq: ADAG) announced its senior management will participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference from November 9-11, 2026, in Boston, MA. The company will host a fireside chat and one-on-one meetings, with a webcast of the fireside chat available on its investor website. Adagene, a clinical-stage biotechnology company, specializes in developing novel antibody-based cancer immunotherapies using computational biology and AI, including its SAFEbody precision masking technology.
Adagene Inc. is developing Muzastotug (ADG126), an immunotherapy for advanced MSS colorectal cancer. Early trials show promising response rates in combination with Keytruda. Investors are anticipating randomized Phase 2 results in the first half of 2027.